Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study

scientific article published on 6 November 2007

Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/SJ.BJC.6604074
P932PMC publication ID2360270
P698PubMed publication ID17987035
P5875ResearchGate publication ID5859824

P50authorPaola UliviQ39596199
Oriana NanniQ43073188
P2093author name stringW Zoli
R Silvestrini
G L Frassineti
E Pasquini
M Ballardini
R Gunelli
M Fiori
G L Pappagallo
N Giovannini
E Bercovich
P2860cites workA phase I clinical, plasma, and cellular pharmacology study of gemcitabineQ28334915
New colorimetric cytotoxicity assay for anticancer-drug screeningQ29615418
Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.Q33343442
Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group studyQ33365072
A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder CancerQ33504597
Improved patient outcomes with BCG immunotherapy vs. chemotherapy - Swedish and worldwide experienceQ33781017
In vitro preclinical models for a rational design of chemotherapy combinations in human tumorsQ34133637
Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter studyQ40496147
Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitroQ40587184
The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference CommitteeQ40831782
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systemsQ41055471
Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic studyQ44315406
Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation.Q44791621
Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC).Q45014818
In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II).Q46082232
Optimal two-stage designs for phase II clinical trialsQ46412217
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancerQ46610841
Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability.Q46634674
Treatment of Bacillus Calmette-Guerin refractory superficial bladder cancer: further intravesical therapyQ46704520
Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.Q53617199
Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trialsQ64112022
Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogsQ73025541
5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study GroupQ74614253
P433issue11
P407language of work or nameEnglishQ1860
P921main subjectbladder cancerQ504775
P1104number of pages6
P304page(s)1499-1504
P577publication date2007-11-06
P1433published inBritish Journal of CancerQ326309
P1476titleActivity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study
P478volume97

Reverse relations

cites work (P2860)
Q39634997Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model
Q39315907Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines.
Q43159409Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial
Q41434863Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer
Q37982150Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review
Q38063552Intravesical therapies for bladder cancer - indications and limitations.
Q37053724Novel Simulation Model of Non-Muscle Invasive Bladder Cancer: A Platform for a Virtual Randomized Trial of Conservative Therapy vs. Cystectomy in BCG Refractory Patients.
Q84060912Phase II study of biweekly gemcitabine as first line therapy in CIS of the bladder: what does an aborted trial tell us?
Q33962426SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin
Q82497871Second-Line Intravesical Gemcitabine in High Risk Superficial Bladder Cancer: Our Experience
Q90116225Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin

Search more.